ShRNA for targeted silencing ALIX gene expression, lentiviral expression vector and application

By designing a shRNA lentiviral vector that targets the ALIX gene, the expression of the ALIX gene in gastric cancer cells was interfered with, solving the problem of poor treatment efficacy in existing gastric cancer technologies and achieving effective inhibition of gastric cancer cells.

CN118910050AActive Publication Date: 2024-11-08WEIHAI MUNICIPAL HOSPITAL
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410973773.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

The lack of specific inhibitory methods targeting the ALIX gene in gastric cancer cells in current technologies leads to low early diagnosis rates and poor treatment outcomes for gastric cancer.

Method used

We designed and constructed a lentiviral expression vector for shRNA that targets and silences the ALIX gene. By infecting human gastric cancer cells and monocytes with the lentivirus, we interfered with the transcription and translation of the ALIX gene and inhibited its expression.

Benefits of technology

It significantly inhibits the migration and growth rate of gastric cancer cells, providing a new, highly effective, specific, and low-side-effect treatment strategy for gastric cancer, which has significant therapeutic implications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910050A_ABST
    Figure CN118910050A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical biology, in particular to shRNA for targeted silencing ALIX gene expression, a lentiviral expression vector and application. The shRNA (short hairpin Ribonucleic Acid) expressed by the targeted silencing ALIX gene comprises shALIX-1 and / or shALIX-2; the nucleotide sequence of the target site of the shALIX-1 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the target site of the shALIX-2 is as shown in SEQ ID NO. 2. The shRNA designed by the invention is packaged into a lentivirus through a lentiviral vector to infect human gastric cancer cells and mononuclear cells, and can be combined with mRNA of an ALIX gene to efficiently interfere with transcription and translation of the ALIX gene, reduce expression of the ALIX gene in the gastric cancer cells and mononuclear cells and inhibit migration of the cells; the growth rates of gastric cancer cells MGC803 and monocytes THP-1 are remarkably inhibited, and the compound has very important significance on treatment of gastric cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical biotechnology, and in particular to a shRNA, a lentiviral expression vector and an application thereof for targeting and silencing ALIX gene expression. Background Art

[0002] Gastric cancer is one of the most common malignant tumors, with an incidence rate ranking fifth among malignant tumors worldwide and an extremely high mortality rate. According to the 2020 statistics of the International Agency for Research on Cancer (IARC), the number of cases and deaths of gastric cancer in my country accounted for 44% and 48.6% of the world's total, respectively. Therefore, the prevention and treatment of gastric cancer is a huge challenge facing the prevention and control of malignant tumors in my country.

[0003] A large amount of research data shows that the clinical treatment effect of gastric cancer is closely related to the early or late diagnosis of gastric cancer. Early gastric cancer can be cured under the premise of active treatment. If it is advanced or advanced gastric cancer, the five-year survival rate will be greatly reduced. At this stage, the treatment of gastric cancer is mainly endoscopic surgery and drug therapy. However, since routine gastric cancer early screening has not been carried out on a large scale in China, the early diagnosis rate is low, the invasiveness is strong, the spread is fast, and the diagnostic and treatment effects of related drugs used in clinical treatment are not good. Therefore, the discovery and application of new targeted markers are crucial for the diagnosis and treatment of gastric cancer.

[0004] Programmed cell death 6-interacting protein (PDCD6IP), also known as ALG2-interacting protein X (ALIX), is one of the multifunctional cytoplasmic and multidomain scaffold proteins that has been studied more intensively in recent years. ALIX is ubiquitously expressed in cells and plays a series of important functions in endosomal pathways, viral budding, cytoskeletal dynamics, cell proliferation and apoptosis. Studies have shown that ALIX is enriched in the exosomes of prostate cancer cell lines compared with those of non-cancerous prostate cell lines; ALIX can regulate tumor-mediated immunosuppression by controlling epidermal growth factor receptor (EGFR) activity and programmed death ligand (PD-L1) presentation and is closely related to the TNM stage and metastasis of pancreatic cancer. However, there is little research on ALIX in gastric cancer. Therefore, exploring its role is of great significance for the early diagnosis and treatment of gastric cancer.

[0005] RNA interference (RNAi) is a phenomenon that inhibits the expression of specific genes in normal organisms. It is a technology that relies on short double-stranded RNA sequences to achieve post-transcriptional gene silencing. It refers to the phenomenon that when double-stranded RNA (dsRNA) homologous to the endogenous mRNA coding region is introduced into the cell, the mRNA is degraded, resulting in gene expression silencing. The reverse strand of the small interfering RNA (siRNA) produced after the exogenous dsRNA enters the cell forms a silencing complex (RISC) with a variety of nucleases. RISC has the function of binding and cutting mRNA to mediate the RNA interference process. At present, the commonly used RNAi technologies in the laboratory mainly include siRNA oligonucleotide vectors and shRNA lentiviral plasmid expression vectors. Short hairpin RNA (shRNA) can be kept stable through virus-mediated transfection, which can reduce off-target effects. RNAi is specific and efficient. This technology has become an important tool for studying gene function and will play an important role in the treatment of viral diseases, genetic diseases and tumors.

[0006] shRNA is first inserted into a lentiviral vector to form a recombinant lentiviral plasmid. The lentiviral plasmid and other auxiliary plasmids form lentivirus with the help of 293T cells, and finally the cells are transfected with lentivirus to exert the silencing effect of shRNA. Under the action of endonucleases, shRNA is cleaved into nucleotide chains, consisting of a forward chain and a reverse chain. The reverse chain combines with a specific enzyme to form an RNA-induced silencing complex RISC (the RISC complex contains siRNA, exonucleases, endonucleases, and helicases). The nucleotide double strands will be depolymerized into two single strands by the activated RISC, and then the reverse chain recognizes and binds to the homologous target mRNA. Under the guidance of the reverse chain, the activated RISC will cut the specific position of the target mRNA, and the cut mRNA will be specifically degraded by the enzymes in the RISC complex, thereby blocking the genetic information transmission of mRNA.

[0007] Targeted drugs designed for cancer cell-related genes have been gradually applied in clinical practice. However, there is currently no shRNA designed specifically for the ALIX gene of gastric cancer cells using shRNA technology. In view of this, the present invention is proposed. Summary of the invention

[0008] The present invention provides a shRNA, a lentiviral expression vector and an application for targeting silencing ALIX gene expression. The designed shRNA molecules are packaged into lentiviruses through lentiviral vectors and then infect human gastric cancer cells and monocytes. The shRNA molecules can bind to the mRNA of the ALIX gene, efficiently interfere with its transcription and translation, reduce the expression of the ALIX gene in gastric cancer cells and monocytes, and inhibit cell migration. The growth rates of gastric cancer cells MGC803 and monocytes THP-1 are significantly inhibited, which is of great significance for the treatment of gastric cancer and solves the problems existing in the prior art.

[0009] The present invention provides one of the following technical solutions:

[0010] A shRNA targeting silencing ALIX gene expression, the shRNA includes shALIX-1 and / or shALIX-2; the target site nucleotide sequence of the shALIX-1 is shown in SEQ ID NO. 1, and the target site nucleotide sequence of the shALIX-2 is shown in SEQ ID NO. 2. Screening experiments have shown that the shRNA can effectively inhibit the expression of the ALIX gene.

[0011] Furthermore, the forward chain sequence of the prepared shALIX-1 is shown in SEQ ID NO.3, and the reverse chain sequence is shown in SEQ ID NO.4.

[0012] Furthermore, the forward chain sequence of the prepared shALIX-2 is shown in SEQ ID NO.5, and the reverse chain sequence is shown in SEQ ID NO.6.

[0013] The present invention provides the following technical solution:

[0014] A lentiviral expression vector comprising the shRNA described above.

[0015] Furthermore, the lentiviral expression vector is obtained by cloning shALIX-1 and / or shALIX-2 into a lentiviral expression vector. The lentiviral expression vector may be pLKO.1.

[0016] The method for constructing the lentiviral expression vector as described above comprises the following steps:

[0017] S1, synthesizing shALIX-1 sequence and / or shALIX-2 sequence by primer annealing;

[0018] S2. Clone the synthesized shALIX-1 and / or shALIX-2 sequences into a lentiviral expression vector.

[0019] Furthermore, the above construction method also includes the following steps:

[0020] The constructed lentiviral expression vector expressing shRNA targeting silencing ALIX was transferred into Escherichia coli competent cells and inoculated into LB liquid culture medium containing ampicillin (Amp) overnight. After obtaining the bacterial precipitate, endoribonuclease was added for enzyme digestion, and the positive plasmids digested by enzyme digestion were sequenced for verification.

[0021] The present invention provides the following technical solution three:

[0022] Application of the above shRNA in preparing drugs for inhibiting ALIX gene expression.

[0023] The use of the above shRNA in the preparation of biological preparations for the treatment / prevention of gastric cancer.

[0024] The present invention also provides the following technical solution 4:

[0025] A preparation for treating gastric cancer, comprising the aforementioned shRNA targeting silencing ALIX gene expression.

[0026] Furthermore, the preparation for treating gastric cancer also includes a pharmaceutically acceptable carrier or adjuvant, diluent or excipient.

[0027] The above-mentioned "pharmaceutically acceptable" means that when the molecular entities and compositions are properly administered to animals or humans, they will not produce adverse, allergic or other adverse reactions. "Pharmaceutically acceptable carriers or excipients" should be compatible with the active ingredient, that is, they can be mixed with it without significantly reducing the effect of the drug under normal circumstances. Specific examples of some substances that can be used as pharmaceutically acceptable carriers or excipients are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethylcellulose and methylcellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; colorants; flavoring agents; tableting, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffer, etc. These substances are used as needed to help the stability of the formulation or to help improve the activity or its biological effectiveness or to produce an acceptable taste or smell in the case of oral administration.

[0028] Furthermore, the dosage form of the above preparation can be made into injection, oral liquid, tablet, capsule, pill, spray.

[0029] The present invention also provides the following technical solution 5:

[0030] A targeted silencing ALIX gene, wherein the target sequence is shown as SEQ ID NO.1 or SEQ ID NO.2.

[0031] Beneficial effects of the present invention:

[0032] 1. The present invention designs and synthesizes shRNA molecules based on the mRNA sequence of the ALIX gene, and constructs the oligonucleotide sequence of the shRNA. The two pairs of shRNA sequences obtained, such as SEQ ID NO.1 and SEQ ID NO.2, are packaged into lentivirus through a lentiviral vector and then infect human gastric cancer cells and mononuclear macrophages, which can bind to the mRNA of the ALIX gene, efficiently interfere with its transcription and translation, reduce the expression of the ALIX gene in gastric cancer cells and mononuclear macrophages, and inhibit cell migration, showing obvious effects.

[0033] 2. The above shRNA sequence designed by the present invention can significantly inhibit the growth rate of gastric cancer cell MGC803, which is of great significance for the treatment of gastric cancer. It provides a theoretical basis for a new strategy for gastric cancer treatment with ALIX-related preparations as the core, and is expected to be applied to the preparation of anticancer gene drugs with high efficiency, strong specificity and few side effects, especially for the research and development of gastric cancer gene drug preparations, which has huge social and economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is a Western blot (WB) diagram of the expression level of ALIX gene in MGC803 cells by shALIX of the present invention;

[0035] Figure 2 This is a WB graph of the expression level of ALIX gene in THP-1 cells by shALIX of the present invention;

[0036] Figure 3 This is a WB graph of the expression level of the ALIX gene in MGC803 cells by the comparative example siRNA sequence in Example 4;

[0037] Figure 4 WB graph of the expression level of ALIX gene in MGC803 cells by four different shALIX sequences constructed in Example 5;

[0038] Figure 5 This is a diagram showing the effect of the shALIX sequence in Example 6 on the proliferation of MGC803 cells.

[0039] in, Figure 1 A in the middle shows the status of MGC803 cells before and after ALIX gene knockdown by shALIX. Figure 1 Middle B is the WB detection result of the expression level of MGC803 cells before and after ALIX gene knockdown by shALIX;

[0040] Figure 2 A in the middle shows the status of THP-1 cells before and after ALIX gene knockdown by shALIX. Figure 2 Middle B is the WB detection result of the expression level of THP-1 cells before and after ALIX gene knockdown by shALIX;

[0041] Figure 1-Figure 5 In the figure, GAPDH is the internal reference protein, NC is the control group infected with the pLKO.1 empty vector, and shALIX-1# and shALIX-2# are the experimental groups infected with pLKO.1-shALIX-1# and pLKO.1-shALIX-2#, respectively. DETAILED DESCRIPTION

[0042] In order to clearly illustrate the technical features of the present invention, the present invention is described in detail below through specific implementation methods in conjunction with the accompanying drawings.

[0043] The sources of some of the materials and reagents used in the following examples are as follows: shALIX-1 and shALIX-2 sequences were synthesized by Yixin Biotechnology (Shanghai) Co., Ltd., plasmids pLKO.1, psPAX2 and pMD2.G were purchased from Ubest Biotechnology, and transfection reagent Lipofectamine 2000 was purchased from Thermo Fisher Scientific (China) Co., Ltd.

[0044] In the following examples, if no specific conditions are specified, all are carried out under conventional conditions or conditions recommended by the manufacturer. If no manufacturer is specified for the reagents or instruments used, all are conventional products that can be purchased commercially. Unless otherwise specified, the present invention adopts the prior art in this field.

[0045] Example 1 Construction of lentiviral vector

[0046] The mRNA sequence of the human ALIX gene (NM_013374) was obtained from the GenBank database (http: / / www.ncbi.nlm.nih.gov / genbank). According to the shRNA design principle, shRNA targeting the human ALIX gene was designed. The target sequences are shown in Table 1, which are used to silence the human ALIX gene.

[0047] The nucleotide sequences of the shRNA target sites and the forward and reverse strand sequences for preparing shRNA are shown in Table 1.

[0048] Table 1

[0049]

[0050] The above four double-stranded oligonucleotide short fragments were connected to the double-enzyme-digested lentiviral vector pLKO.1 vector. The ligation product was inoculated into 30-50 mL of LB liquid culture medium containing Amp by Escherichia coli containing the target plasmid, placed in a 37°C constant temperature shaker, 200 rpm / min, and incubated for 12-16 hours; the cultured bacterial solution was taken out from the shaker, centrifuged at 3500-5000g for 10 minutes at room temperature; the supernatant was aspirated, and the excess culture medium on the container wall was discarded to obtain a bacterial precipitate. 2.5 mL of Solution I (RNase A was added) was added to the precipitate, and the bacterial precipitate was resuspended by vortexing; the bacterial cells were collected to extract the plasmid, the plasmid was verified by enzyme digestion, and the positive plasmid of enzyme digestion was sent to BGI for sequencing verification. Sequencing showed that the successfully constructed lentiviral plasmid was used for subsequent experiments.

[0051] By the above method, lentiviral vectors pLKO.1-shALIX-1# and pLKO.1-shALIX-2# containing the target plasmid were constructed respectively.

[0052] Example 2: Preparation of cell lentivirus and lentiviral transfection of cells

[0053] Refer to the instructions of Lipofectamine 2000 reagent to package lentivirus.

[0054] The cells were transfected with the two lentiviral vectors prepared in Example 1 as the experimental group, and the cells were transfected with the empty vector pLKO.1 as the control group. The core plasmid (pLKO.1-shALIX-1#, pLKO.1-ALIX-2# or pLKO.1) and the packaging plasmid (psPAX2 and pMD2.G) were transferred into 293T cells by lipofectmin2000, and the virus was prepared and collected. Then, the human gastric cancer cell MCG803 and the monocytic cell THP-1 were infected with the lentivirus containing the target shALIX sequence, and the resistant cells were selected by puromycin for the experiment.

[0055] Lentivirus packaging was performed in 293T cells (cell density was required to be about 90%). Lipofectamine-2000 transfection reagent was added to 150 μL serum-free culture medium and allowed to stand for 5 minutes; packaging plasmid psPAX2 and pMD2.G were added to 150 μL serum-free culture medium at a ratio of 3:1, with a total of 1.5 μg and 1.5 μg of core plasmid;

[0056] Add the transfection mixture to the cell culture medium of a 35mm cell culture dish and mix well. After 6-8 hours, replace with 2mL of fresh DMEM complete medium (10% FBS); collect the virus after 36-48 hours, centrifuge at 8000g for 5 minutes, collect all the supernatant, filter through a 0.45μm filter membrane, transfer the virus supernatant to a new collection tube, and store at -20℃.

[0057] The viral supernatant obtained by lentivirus packaging was used to infect MGC803 cells and THP-1 cells (the cell inoculation density was controlled at about 50%). The amount of virus to be added was determined according to the virus titer, and 10 μg / μL of polybrene (1:1000 dilution) was added at the same time to accelerate the entry of the virus into the cells through the electric charge. The medium was changed after 12 hours, and the virus was expressed in the cells after 24 to 48 hours. After 48 hours of infection, fresh culture medium containing puromycin (1 μg / mL) was replaced. The medium was changed once every 2 days, and positive clones were selected for detection after about 7 days.

[0058] Example 3: Western blot detection of ALIX gene protein expression level in MGC803 cells and THP-1 cells

[0059] The virus-infected MGC803 cells and THP-1 cells obtained in Example 2 were collected, and the total protein was extracted and the protein concentration was determined. After the protein was denatured, it was transferred to the membrane after running on the gel. After the membrane was blocked with 5% skim milk for 2 hours, it was incubated overnight with ALIX antibody and GAPDH antibody, and then incubated with goat anti-mouse antibody linked to horseradish peroxidase at room temperature for 1 hour. After the antibody incubation, the membrane was washed 3 times with TBS-T solution at room temperature, and after 5 minutes each time, it was developed with BeyoECL Plus (ultrasensitive ECL chemiluminescence kit) in ChemiDocTM XRS+ (Bio-Rad) imaging system. WB detected the expression of the target protein ALIX in different groups of cells. The experimental results are shown in the figure. Figure 1 , Figure 2 shown.

[0060] Depend on Figure 1 , Figure 2 It can be seen that compared with the control group NC, both shALIX-1# and shALIX-2# can significantly silence the expression of ALIX protein in MGC803 cells and THP-1 cells, and have a significant knockdown effect on the expression of ALIX in MGC803 cells and THP-1 cells.

[0061] Embodiment 4:

[0062] The following three groups of siRNA sequences were used for Western blot detection according to the method of Example 3 and compared with the shRNA in Example 1. The experimental results are as follows: Figure 3 As shown. It shows that the following three groups of siRNA sequences cannot effectively silence the expression of ALIX in MGC803 cells.

[0063] siALIX-1F:CGAUUUGGUUAACAGAUCA (SEQ ID NO.7);

[0064] siALIX-1R:UGAUCUGUUAACCAAAUCG (SEQ ID NO. 8).

[0065] siALIX-2F:GAUCGAGUUCCAGACCUUA (SEQ ID NO.9);

[0066] siALIX-2R: UAAGGUCUGGAACUCGAUC (SEQ ID NO. 10).

[0067] siALIX-3F: GCUCAAGAUGGUGUGUAAA (SEQ ID NO. 11);

[0068] siALIX-3R: UUAUCACACCAUCUUGAGC (SEQ ID NO. 12).

[0069] Example 5

[0070] According to the method of Example 1, 4 groups of shRNA sequences targeting the human ALIX gene were constructed in the experiment. According to the method of Example 3, the other 2 groups of shRNAs were subjected to WB detection with the shRNAs of the target sequences in Table 1. The effect comparison results are as follows: Figure 4 As shown, it is suggested that compared with shRNAs of other sequences, shRNA-1# and shRNA-2# of the present invention can achieve more significant and effective expression of ALIX in MGC803 cells.

[0071] The target site nucleotide sequences of the other two groups of shRNAs and the forward and reverse chain sequences for preparing the corresponding shRNAs are shown in Table 2.

[0072] Table 2

[0073]

[0074] Example 6: Clonal plaque formation assay to detect the effect of shALIX on MGC803 cell proliferation

[0075] The virus-infected MGC803 cells obtained in Example 2 were collected, and cells transfected with the pLKO.1 empty vector were used as a control group.

[0076] Take cells in good logarithmic growth state, digest them with trypsin for 3-5 minutes, add culture medium to neutralize, centrifuge at 1000g for 3-5 minutes, rinse twice with PBS, remove the supernatant, and suspend the cells in complete culture medium for later use.

[0077] The cell suspension was diluted as needed and inoculated into the culture plate. The cells were gently mixed to resuspend and placed in a 37°C 5% CO 2 Culture the cells in a cell culture incubator for 2 to 3 weeks.

[0078] Observe the culture dish with naked eyes, and stop culturing when obvious cloned cell clusters appear. Wash with PBS, add 4% paraformaldehyde, and let stand for 15 minutes. Remove the fixative, wash with PBS, add GIMSA staining solution and let stand for 10-15 minutes, rinse repeatedly and air dry.

[0079] The plate was inverted and photographed, and the number of clone spots was counted using Image J software.

[0080] The experimental results are as follows Figure 5 Compared with the control group, shALIX had a significant inhibitory effect on the proliferation of MGC803 cells (*P<0.05).

[0081] The above specific implementation manner cannot be used as a limitation on the protection scope of the present invention. For those skilled in the art, any substitution, improvement or change made to the implementation manner of the present invention falls within the protection scope of the present invention.

[0082] The matters not described in detail in the present invention are all known technologies to those skilled in the art.

Claims

1. A shRNA targeting silencing ALIX gene expression, characterized in that: The shRNA includes shALIX-1 and / or shALIX-2; the target site nucleotide sequence of the shALIX-1 is shown in SEQ ID NO.1, and the target site nucleotide sequence of the shALIX-2 is shown in SEQ ID NO.

2.

2. The shRNA targeting silencing ALIX gene expression according to claim 1, characterized in that: The forward chain sequence of the shALIX-1 prepared is shown in SEQ ID NO.3, and the reverse chain sequence is shown in SEQ ID NO.

4.

3. The shRNA targeting silencing ALIX gene expression according to claim 1, characterized in that: The forward chain sequence of the shALIX-2 prepared is shown in SEQ ID NO.5, and the reverse chain sequence is shown in SEQ ID NO.

6.

4. A lentiviral expression vector comprising the shRNA according to any one of claims 1 to 3.

5. The lentiviral expression vector according to claim 4, characterized in that The lentiviral expression vector is obtained by cloning shALIX-1 and / or shALIX-2 into a lentiviral expression vector.

6. Use of the shRNA according to any one of claims 1 to 3 in the preparation of a drug for inhibiting ALIX gene expression.

7. Use of the shRNA according to any one of claims 1 to 3 in the preparation of biological agents for the treatment / prevention of gastric cancer.

8. A preparation for treating gastric cancer, characterized in that: The method comprises the shRNA targeting silencing ALIX gene expression as described in any one of claims 1 to 3.

9. A targeted silencing ALIX gene, characterized in that: The target sequence is shown as SEQ ID NO.1 or SEQ ID NO.2.

Citation Information

Patent Citations

  • Screening assay

    CN101107528A

  • Microvesicle, and manufacturing method for same

    CN105209617A

  • Medicine for treating gastric cancer cells and gastric cancer stem cells and application of medicine

    CN115350176A

  • Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer

    US20180104187A1

  • Method of Diagnosing Gastric Cancers Using MicroRNAs

    US20220081722A1